The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Prior history of a malignancy other than cutaneous basal cell or cervical carcinomas. * Other significant, chronic underlying medical illness which would impair study completion. * Liver dysfunction as demonstrated by lab results. * Laboratory evidence of compromised bone marrow function. Concurrent Medication: Excluded: * Any other experimental agents. * Any probenecid-containing product. Patients are excluded if they have a history of symptoms characteristic of CDC class I or IV including any of the following: * Unintentional weight loss of greater than 10 lbs, or more than 10 percent of usual body weight within the last 16 weeks. * Unexplained fever \> 38.5 degrees C on more than 14 consecutive days or on more than 15 days in the previous 30-day period. * Unexplained diarrhea defined by = or \> 2 liquid stools per day persisting for = or \> 14 days or 15 days in any 30-day period. * OR History of secondary infections associated with AIDS related complex (ARC) including: * Recurrent oral candidiasis documented by morphology or by response to antifungal therapy within 3 years. * Herpes zoster infection within 3 years. * Oral hairy leukoplakia at any time. * OR History of opportunistic disease fulfilling the CDC surveillance definition of AIDS. * Signs and symptoms at baseline characteristic of acute HIV disease (CDC group I). * Evidence of significant neurologic dysfunction as currently defined by CDC following standard neurologic screening and AIDS Dementia Assessment. Prior Medication: Excluded: \- Previous treatment for greater than 3 months duration with any antiretroviral compound such as zidovudine (AZT). Excluded within 4 weeks of study entry: \- Treatment with any potentially myelosuppressive drug, nephrotoxic agent, or other experimental therapy. Excluded within 3 months of study entry: \- Antiretroviral drugs or biologic response modifiers. Excluded within 4 months of study entry: \- Systemic corticosteroids. Patients must meet the following criteria: * HIV infection demonstrated by ELISA and confirmed by Western blot. * Signs and symptoms of HIV disease limited to those characteristic of CDC groups II (asymptomatic) and III (persistent generalized lymphadenopathy - PGL). * Ability to give informed consent. * Willingness to be followed by the originating medical center for the entire 3-year duration of the study. Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.